John McHutchi­son throws in the tow­el on HBV drug, trig­ger­ing lay­offs as As­sem­bly shifts to next-gen ap­proach­es

When As­sem­bly Bio­sciences dis­closed in 2020 that its lead ex­per­i­men­tal he­pati­tis B drug ve­bi­corvir, in com­bi­na­tion with nu­cle­o­side ther­a­py, couldn’t of­fer the func­tion­al cure …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER